Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease.

Drug-loaded, brain-targeted nanocarriers could be a promising tool in overcoming the challenges associated with Alzheimer's disease therapy. These nanocargoes are enormously flexible to functionalize and facilitate the delivery of drugs to brain cells by bridging the blood-brain barrier and into brain cells. To date, modifications have included nanoparticles (NPs) coating with tunable surfactants/phospholipids, covalently attaching polyethylene glycol chains (PEGylation), and tethering different targeting ligands to cell-penetrating peptides in a manner that facilitates their entry across the BBB and downregulates various pathological hallmarks as well as intra- and extracellular signaling pathways. This review provides a brief update on drug-loaded, multifunctional nanocarriers and the therapeutic intervention of autophagy and stem cells in the management of Alzheimer's disease.

[1]  Fengna Chu,et al.  Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab , 2022, Frontiers in Aging Neuroscience.

[2]  S. Samson,et al.  Sensorimotor Synchronization in Healthy Aging and Neurocognitive Disorders , 2022, Frontiers in Psychology.

[3]  Anonymous,et al.  2022 Alzheimer's disease facts and figures , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  Yuan Zhang,et al.  Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer’s Disease: A Review , 2022, Biomedicines.

[5]  Fen-fang Hong,et al.  Role of Cholinergic Signaling in Alzheimer’s Disease , 2022, Molecules.

[6]  T. Saleh,et al.  Naturally Occurring Antioxidant Therapy in Alzheimer’s Disease , 2022, Antioxidants.

[7]  J. Matías‐Guiu,et al.  Presenilin mutations and their impact on neuronal differentiation in Alzheimer’s disease , 2021, Neural regeneration research.

[8]  J. Mytych.  Klotho and neurons: mutual crosstalk between autophagy, endoplasmic reticulum, and inflammatory response , 2021, Neural regeneration research.

[9]  A. Bozkır,et al.  ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood–Brain Barrier , 2020, Pharmaceutics.

[10]  Münteha Nur Sonuç Karaboğa,et al.  Analysis of Tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: Towards Alzheimer's disease detection. , 2020, Talanta.

[11]  S. Reis,et al.  RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer’s Disease , 2020, Pharmaceutical Research.

[12]  R. Nixon.  The aging lysosome: An essential catalyst for late-onset neurodegenerative diseases. , 2020, Biochimica et Biophysica Acta - Proteins and Proteomics.

[13]  S. Reis,et al.  Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  K. P. Devi,et al.  Deciphering the anti-apoptotic potential of α-bisabolol loaded solid lipid nanoparticles against Aβ induced neurotoxicity in Neuro-2a cells. , 2020, Colloids and surfaces. B, Biointerfaces.

[15]  A. Rauf,et al.  Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease , 2020, Molecules.

[16]  D. Ecker,et al.  An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement , 2020, Molecular therapy. Nucleic acids.

[17]  Lu Zhang,et al.  Immunomodulatory role of mesenchymal stem cells in Alzheimer's disease. , 2020, Life sciences.

[18]  S. Papageorgiou,et al.  Current and Future Treatments in Alzheimer Disease: An Update , 2020, Journal of central nervous system disease.

[19]  C. Lopes,et al.  Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  Liang Zhao,et al.  Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles , 2020, Drug delivery.

[21]  Jin-lan Jiang,et al.  Current status and future prospects of stem cell therapy in Alzheimer’s disease , 2019, Neural regeneration research.

[22]  P. Reddy.  Current status of stem cell research: An editorial. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[23]  M. Koziorowski,et al.  Klotho-mediated changes in the expression of Atg13 alter formation of ULK1 complex and thus initiation of ER- and Golgi-stress response mediated autophagy , 2019, Apoptosis.

[24]  Zhongjie Sun,et al.  Autophagy plays a critical role in Klotho gene deficiency-induced arterial stiffening and hypertension , 2019, Journal of Molecular Medicine.

[25]  B. Sochanowicz,et al.  Diminished amyloid-β uptake by mouse microglia upon treatment with quantum dots, silver or cerium oxide nanoparticles: Nanoparticles and amyloid-β uptake by microglia , 2019, Human & experimental toxicology.

[26]  D. G. Parambi,et al.  Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives , 2019, The Journal of pharmacy and pharmacology.

[27]  Absar Ahmad,et al.  Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease , 2019, ACS omega.

[28]  A. Camins,et al.  Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Fang Huang,et al.  Enhanced Expression of Secreted α-Klotho in the Hippocampus Alters Nesting Behavior and Memory Formation in Mice , 2019, Front. Cell. Neurosci..

[30]  S. Antimisiaris,et al.  Preparation of Benzothiazolyl-Decorated Nanoliposomes , 2019, Molecules.

[31]  J. Cladera,et al.  Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[32]  A. Grumezescu,et al.  Neurotoxicity of Nanomaterials: An Up-to-Date Overview , 2019, Nanomaterials.

[33]  Wilson Barnabas,et al.  Drug targeting strategies into the brain for treating neurological diseases , 2019, Journal of Neuroscience Methods.

[34]  Chuanlu Jiang,et al.  Nanocomposites Inhibit the Formation, Mitigate the Neurotoxicity, and Facilitate the Removal of β-Amyloid Aggregates in Alzheimer's Disease Mice. , 2018, Nano letters.

[35]  Jianqing Gao,et al.  Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances , 2018, Asian journal of pharmaceutical sciences.

[36]  M. Masserini,et al.  Nanomedicine for the Treatment of Alzheimer's Disease. , 2015, Journal of biomedical nanotechnology.

[37]  M. Salehi,et al.  Will Nanotechnology Bring New Hope for Stem Cell Therapy? , 2019, Cells Tissues Organs.

[38]  A. Volceanov,et al.  Impact of Nanoparticles on Brain Health: An Up to Date Overview , 2018, Journal of clinical medicine.

[39]  R. Dinarvand,et al.  Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation , 2018, DARU Journal of Pharmaceutical Sciences.

[40]  M. Koziorowski,et al.  Klotho modulates ER-mediated signaling crosstalk between prosurvival autophagy and apoptotic cell death during LPS challenge , 2018, Apoptosis.

[41]  Z. Shinwari,et al.  Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities , 2018, Front. Aging Neurosci..

[42]  M. Dehouck,et al.  A nanoformulation for the preferential accumulation in adult neurogenic niches , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[43]  K. Yung,et al.  Effects of rhynchophylline on the hippocampal miRNA expression profile in ketamine-addicted rats , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  S. Mohammadi-Samani,et al.  Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages , 2018, Research in pharmaceutical sciences.

[45]  Yao-Xin Lin,et al.  A self-destructive nanosweeper that captures and clears amyloid β-peptides , 2018, Nature Communications.

[46]  G. Bhagat,et al.  Disruption of the beclin 1/Bcl-2 autophagy regulatory complex promotes longevity in mice , 2018, Nature.

[47]  M. Kamal,et al.  Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[48]  A. Silva,et al.  Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization , 2018, Journal of Nanobiotechnology.

[49]  Hong Zhang,et al.  Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease. , 2018, ACS nano.

[50]  M. Masserini,et al.  Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[51]  M. Alonso,et al.  Nose-to-brain peptide delivery - The potential of nanotechnology. , 2017, Bioorganic & medicinal chemistry.

[52]  Yongzhong Du,et al.  Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability. , 2018, Colloids and surfaces. B, Biointerfaces.

[53]  S. K. Mehta,et al.  Anti-Alzheimer's potential of berberine using surface decorated multi-walled carbon nanotubes: A preclinical evidence. , 2017, International journal of pharmaceutics.

[54]  A. Camins,et al.  New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[55]  M. Salmona,et al.  Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof‐of‐concept , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[56]  B. Narasimhan,et al.  Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[57]  B. Cullen,et al.  Update on Alzheimer's Disease Therapy and Prevention Strategies. , 2017, Annual review of medicine.

[58]  F. Wandosell,et al.  ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. , 2017, Biomaterials.

[59]  Liping Huang,et al.  β-asarone improves learning and memory and reduces Acetyl Cholinesterase and Beta-amyloid 42 levels in APP/PS1 transgenic mice by regulating Beclin-1-dependent autophagy , 2016, Brain Research.

[60]  A. Pugazhendhi,et al.  A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: Formation mechanism and applications. , 2016, Enzyme and microbial technology.

[61]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[62]  T. Webster,et al.  A Special Section on The Role of Nanotechnology in Stem Cell Research , 2016 .

[63]  M. Martorell,et al.  Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease. , 2016, Current pharmaceutical biotechnology.

[64]  Raquel Ferreira,et al.  Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[65]  K. Chopra,et al.  Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations , 2016, Drug delivery.

[66]  A. Neves,et al.  Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E , 2016, Journal of Nanobiotechnology.

[67]  Blanka Klimova,et al.  Speech and language impairments in dementia , 2016 .

[68]  Merve Gultekinoglu,et al.  Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro , 2016, Journal of Neural Transmission.

[69]  G. Sudhandiran,et al.  Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain. , 2015, The Journal of nutritional biochemistry.

[70]  N. Braidy,et al.  Neuroprotective effects of chrysin: From chemistry to medicine , 2015, Neurochemistry International.

[71]  K. Gomes,et al.  Leptin in Alzheimer's disease. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[72]  D. Marciani.  Alzheimer's disease vaccine development: A new strategy focusing on immune modulation , 2015, Journal of Neuroimmunology.

[73]  Zhi-ru Zhu,et al.  Rhynchophylline Protects Against the Amyloid β-Induced Increase of Spontaneous Discharges in the Hippocampal CA1 Region of Rats , 2015, Neurochemical Research.

[74]  Guanghui Ma,et al.  Nanotheranostics: Congo Red/Rutin‐MNPs with Enhanced Magnetic Resonance Imaging and H2O2‐Responsive Therapy of Alzheimer's Disease in APPswe/PS1dE9 Transgenic Mice , 2015, Advanced materials.

[75]  Y. Li,et al.  Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways , 2015, Molecular medicine reports.

[76]  N. Inestrosa,et al.  Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor Protein and Enhances Its Degradation by Atg5-Dependent Autophagy , 2015, PloS one.

[77]  R. Farid,et al.  Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain , 2015, Drug development and industrial pharmacy.

[78]  D. Drobne,et al.  Nanoparticle interaction with the immune system / Interakcije nanodelcev z imunskim sistemom , 2015, Arhiv za higijenu rada i toksikologiju.

[79]  J. Toyn.  What lessons can be learned from failed Alzheimer’s disease trials? , 2015, Expert review of clinical pharmacology.

[80]  N. Iwata,et al.  Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2015, PloS one.

[81]  Xiaogang Qu,et al.  Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease. , 2015, Chemistry.

[82]  E. Shusta,et al.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. , 2015, Annual review of pharmacology and toxicology.

[83]  M. Barbagallo,et al.  Type 2 diabetes mellitus and Alzheimer's disease. , 2014, World journal of diabetes.

[84]  E. Souto,et al.  Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[85]  M. Kamal,et al.  Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease. , 2014, CNS & neurological disorders drug targets.

[86]  Quan Ma,et al.  Uptake of silica nanoparticles: neurotoxicity and Alzheimer-like pathology in human SK-N-SH and mouse neuro2a neuroblastoma cells. , 2014, Toxicology letters.

[87]  Y. Kuo,et al.  Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. , 2014, Biomaterials.

[88]  Xuhui Huang,et al.  Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer’s disease , 2014, Proceedings of the National Academy of Sciences.

[89]  Charles Duyckaerts,et al.  Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. , 2014, European journal of medicinal chemistry.

[90]  Bhavna,et al.  Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. , 2014, International journal of biological macromolecules.

[91]  S. Amor,et al.  Inflammation in neurodegenerative diseases – an update , 2014, Immunology.

[92]  D. Butterfield,et al.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. , 2014, Biochemical pharmacology.

[93]  T. Saido,et al.  Dual roles for autophagy: Degradation and secretion of Alzheimer's disease Aβ peptide , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.

[94]  M. Cordero,et al.  Coenzyme Q10 Therapy , 2014, Molecular Syndromology.

[95]  Kristen M. Jaruszewski,et al.  Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. , 2014, Biomaterials.

[96]  S. Baboota,et al.  Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting , 2014, Drug development and industrial pharmacy.

[97]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[98]  T. Saido,et al.  Aβ secretion and plaque formation depend on autophagy. , 2013, Cell reports.

[99]  X. Qi,et al.  Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. , 2013, International journal of pharmaceutics.

[100]  M. Stefani,et al.  The Polyphenol Oleuropein Aglycone Protects TgCRND8 Mice against Aß Plaque Pathology , 2013, PloS one.

[101]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[102]  E. Masliah,et al.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. , 2013, Pharmacology & therapeutics.

[103]  G. Pasinetti,et al.  Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models , 2013, Neurobiology of Aging.

[104]  M. Mattson,et al.  Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession , 2013, Neurobiology of Aging.

[105]  V. Pillay,et al.  Ligand-functionalized nanoliposomes for targeted delivery of galantamine. , 2013, International journal of pharmaceutics.

[106]  F. Islam,et al.  Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type , 2013, Neurochemistry International.

[107]  Muriel Noetzli,et al.  Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease , 2013, Clinical Pharmacokinetics.

[108]  S. Gandy,et al.  Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model , 2013, Autophagy.

[109]  O. Forlenza,et al.  Does Lithium Prevent Alzheimer’s Disease? , 2012, Drugs & Aging.

[110]  E. Mandelkow,et al.  Autophagic degradation of tau in primary neurons and its enhancement by trehalose , 2012, Neurobiology of Aging.

[111]  Weize Li,et al.  Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. , 2012, Environmental toxicology and pharmacology.

[112]  M. Nireekshan Kumar,et al.  Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[113]  L. Ferreira,et al.  Nanomedicine boosts neurogenesis: new strategies for brain repair. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[114]  P. Axelsen,et al.  Copper and oxidative stress in the pathogenesis of Alzheimer's disease. , 2012, Biochemistry.

[115]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[116]  P. Gaillard,et al.  Enhanced brain drug delivery: safely crossing the blood-brain barrier. , 2012, Drug discovery today. Technologies.

[117]  C. Huang,et al.  Diabetes as a risk factor for dementia and mild cognitive impairment: a meta‐analysis of longitudinal studies , 2012, Internal medicine journal.

[118]  T. Maekawa,et al.  Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease , 2012, PloS one.

[119]  G. Morfini,et al.  Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells , 2012, Experimental Brain Research.

[120]  Barbara Luppi,et al.  Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[121]  J. Debnath,et al.  Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2011, PLoS ONE.

[122]  Patrick Couvreur,et al.  Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[123]  Sagar R. Mudshinge,et al.  Nanoparticles: Emerging carriers for drug delivery. , 2011, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[124]  N. Inestrosa,et al.  Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing , 2011, Translational Psychiatry.

[125]  E. Schiffrin,et al.  Vascular Mechanisms in the Pathogenesis of Stroke , 2011, Current hypertension reports.

[126]  M. Irizarry.  Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.

[127]  A. Nieoullon.  Neurodegenerative diseases and neuroprotection: current views and prospects , 2011 .

[128]  C. Sutherland,et al.  Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling , 2010, Proceedings of the National Academy of Sciences.

[129]  Ming Yan,et al.  Protective effects of galantamine against Aβ-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress , 2010, Neurochemistry International.

[130]  Sandip S Chavhan,et al.  Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[131]  Doriano Brogioli,et al.  Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.

[132]  H. Sarin.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. , 2010, Therapeutic delivery.

[133]  T. Yamawaki,et al.  Immunopositivity for ESCRT-III subunit CHMP2B in granulovacuolar degeneration of neurons in the Alzheimer's disease hippocampus , 2010, Neuroscience Letters.

[134]  Wenwei Tang,et al.  Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[135]  Sandra Barth,et al.  Autophagy: cellular and molecular mechanisms , 2010, The Journal of pathology.

[136]  Tong-ying Jiang,et al.  Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. , 2010, Biomaterials.

[137]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[138]  Stephen Mann,et al.  Nanoparticles can cause DNA damage across a cellular barrier. , 2009, Nature nanotechnology.

[139]  Dong Hyun Kim,et al.  Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal‐regulated kinase signalling pathway , 2009, British journal of pharmacology.

[140]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[141]  Lewis H Kuller,et al.  Midlife and late-life obesity and the risk of dementia: cardiovascular health study. , 2009, Archives of neurology.

[142]  L. Hanson,et al.  Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System , 2009, Journal of Pharmacology and Experimental Therapeutics.

[143]  Lucienne Juillerat-Jeanneret,et al.  The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.

[144]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[145]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[146]  V. Mok,et al.  Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. , 2008, Journal of clinical psychopharmacology.

[147]  Shrikant D. Mishra,et al.  The effect of curcumin (turmeric) on Alzheimer's disease: An overview , 2008, Annals of Indian Academy of Neurology.

[148]  Ralph A. Nixon,et al.  Autophagy, amyloidogenesis and Alzheimer disease , 2007, Journal of Cell Science.

[149]  F. Baas,et al.  Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation , 2007, Chembiochem : a European journal of chemical biology.

[150]  S. Young,et al.  ESCRT-III Dysfunction Causes Autophagosome Accumulation and Neurodegeneration , 2007, Current Biology.

[151]  J. Henry,et al.  Attenuation of β-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment , 2007, Brain Research.

[152]  Roberto Cappai,et al.  The redox chemistry of the Alzheimer's disease amyloid β peptide , 2007 .

[153]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[154]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[155]  J. Cladera,et al.  Influence of dendrimer's structure on its activity against amyloid fibril formation. , 2006, Biochemical and biophysical research communications.

[156]  M. Pappolla,et al.  Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels , 2006, Neurobiology of Disease.

[157]  H. Tanila,et al.  Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice , 2006, International Journal of Developmental Neuroscience.

[158]  L. Tjernberg,et al.  Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease , 2005, The Journal of cell biology.

[159]  Ralph A. Nixon,et al.  Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study , 2005, Journal of neuropathology and experimental neurology.

[160]  O. Tenovuo.  Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury—clinical experience in 111 patients , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[161]  H. Benson,et al.  Drug delivery across the blood-brain barrier. , 2004, Current drug delivery.

[162]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[163]  W. Frey,et al.  The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. , 2004, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[164]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[165]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[166]  J. Olney,et al.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.

[167]  J. Morris,et al.  Classification of dementia and Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.

[168]  J. Olney,et al.  Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.